IP
Chinese court bans some iPhones over Qualcomm dispute
Qualcomm says the ban covers iPhones 6S through X.
The winners and losers in the new NAFTA
The new deal is preferable to economic chaos.
Canada wants TPP changes on IP, supply management, culture
Expected to be a central topic at a meeting of leaders from the Asia-Pacific Economic Co-operation bloc.
Trump to seek trade probe of China for technology, IP theft
This while seeking Beijing’s help to bring North Korea into line.
-
Leverage legal issues: innovating in a complex regulatory environment
Take advantage of legal issues to boost value and minimize IP risks.
-
Counterfeiter issues? XRCC experts are on the job
The Xerox Research Centre of Canada has developed advanced materials to meet manufacturers’ security challenges.
Sask.’s Wall promises tax incentive for new patents that earn money
Goal is to reward companies that develop and commercialize patents and IP in the province, premier says.
TPP’s IP conditions bad for Canada?
Critics concerned IP conditions puts emerging and innovative entrepreneurs in smaller countries, such as Canada, at a disadvantage.
-
Balsillie fears TPP could cost Canada billions
Intellectual property rules weighted to the US make the deal the “worst ever” policy move.
Memex acquires IP, other assets of Dostek Inc.
Will use technology to enhance DNC capabilities of MERLIN shopfloor OEE platform.
China considers higher caps for IP violations
Cracking down on trade secret theft to encourage innovation.
Ballard signs $1M services agreement with M-Field in Europe
Deal includes engineering services for material handling systems to be deployed in Europe.
US says action needed on growing Chinese hacking that harms trust, Beijing’s interests
Cyber intrusions from China have reached very high levels, adding to existing IP protection problems.
CSA supports changes to counterfeit products act
Combating Counterfeit Products Act toughens Trade-marks and Copyright laws.
Patent protection stirs Canada EU trade talks
Exclusive rights for 10 years feared to drive up drug plan costs.
